OMPI Seminar: Zack Parsons and Rob deKemp

Printer-friendly version
Thursday, December 14, 2017

Time: 3:30 - 5:00 pm -  Refreshments start at 3:15 pm.

Location: Boardroom H-2403, Second Floor, The University of Ottawa Heart Institute, 40 Ruskin Street.


1. Monte Carlo calculation of doses for eye plaque brachytherapy.

By: Zack Parsons, MSc student.

Supervisor: Rowan Thomson.

Abstract: egs_brachy is a new Monte Carlo user code developed by members of the CLRP research group for fast brachytherapy dose calculations. This talk presents recent results obtained with egs_brachy that focus on eye plaque brachytherapy, a treatment widely utilized for ocular melanomas. The use of egs_brachy allows for the development of techniques for a more accurate model based approach to the calculation of dose as opposed to the more generally used TG-43 approximations. The results to be presented include the comparison of dose to previous data for both photon eye plaques and beta-emitting Ru/Rh-106 eye plaques for benchmarking purposes, and the implementation of the new EGSnrc egs_radionuclide source for use with beta-emitting plaques. Future work leading to the simulation of the non-uniformity in beta plaque dose distributions will also be discussed.

2. Title: PET Molecular Imaging of (Para-)Sympathetic Innervation of the Heart: Understanding the (Yin-)Yang Control of Cardiac Function.

By: Rob deKemp, PhD.

Abstract: The autonomic nervous system regulates heart function through a balance of sympathetic (fight-or-flight) and para-sympathetic (rest-and-digest) control signals. Non-invasive imaging of so-called ‘cardiac innervation’ can be performed using radio-labeled tracers, which are generally analogs of the respective neurotransmitters, nor-epinephrine and acetyl-choline. The two most commonly used tracers (I-123-mIBG and C-11 mHED) have been developed for SPECT and PET imaging of the sympathetic nervous system (SNS) in patients with poor cardiac pump function, i.e. those in various stages of heart failure. Imaging and analysis methods vary from planar measurements of relative heart-to-mediastinum ratios, to dynamic volumetric measurements for quantification of receptor or transporter density and activity. Pre-clinical and clinical applications of PET SNS imaging will be shown in diabetes, heart failure, sleep apnea, coronary artery disease and atrial fibrillation.